MX2024006105A - Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme. - Google Patents
Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme.Info
- Publication number
- MX2024006105A MX2024006105A MX2024006105A MX2024006105A MX2024006105A MX 2024006105 A MX2024006105 A MX 2024006105A MX 2024006105 A MX2024006105 A MX 2024006105A MX 2024006105 A MX2024006105 A MX 2024006105A MX 2024006105 A MX2024006105 A MX 2024006105A
- Authority
- MX
- Mexico
- Prior art keywords
- nitroxoline
- prevention
- treatment
- plexiform neurofibroma
- plexiform
- Prior art date
Links
- 201000004404 Neurofibroma Diseases 0.000 title abstract 2
- RJIWZDNTCBHXAL-UHFFFAOYSA-N nitroxoline Chemical compound C1=CN=C2C(O)=CC=C([N+]([O-])=O)C2=C1 RJIWZDNTCBHXAL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005131 nitroxoline Drugs 0.000 title abstract 2
- 208000004748 plexiform neurofibroma Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2116743.2A GB202116743D0 (en) | 2021-11-19 | 2021-11-19 | Treatment |
| PCT/GB2022/052933 WO2023089328A1 (en) | 2021-11-19 | 2022-11-18 | Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006105A true MX2024006105A (es) | 2024-05-30 |
Family
ID=79163954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006105A MX2024006105A (es) | 2021-11-19 | 2022-11-18 | Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250000852A1 (https=) |
| EP (1) | EP4433054A1 (https=) |
| JP (1) | JP2024540439A (https=) |
| KR (1) | KR20240108407A (https=) |
| CN (1) | CN118215479A (https=) |
| AU (1) | AU2022392456A1 (https=) |
| CA (1) | CA3238805A1 (https=) |
| GB (1) | GB202116743D0 (https=) |
| IL (1) | IL312885A (https=) |
| MX (1) | MX2024006105A (https=) |
| WO (1) | WO2023089328A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202218460D0 (en) * | 2022-12-08 | 2023-01-25 | Healx Ltd | Treatment |
| WO2026022492A1 (en) * | 2024-07-26 | 2026-01-29 | Healx Limited | Nitroxoline for use in the treatment and/or prevention of pain |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2641471T3 (es) * | 2008-10-06 | 2017-11-10 | The Johns Hopkins University | Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos |
| GB202108224D0 (en) * | 2021-06-09 | 2021-07-21 | Healx Ltd | Treatment |
-
2021
- 2021-11-19 GB GBGB2116743.2A patent/GB202116743D0/en not_active Ceased
-
2022
- 2022-11-18 CN CN202280074138.9A patent/CN118215479A/zh active Pending
- 2022-11-18 EP EP22812750.2A patent/EP4433054A1/en active Pending
- 2022-11-18 KR KR1020247016458A patent/KR20240108407A/ko active Pending
- 2022-11-18 WO PCT/GB2022/052933 patent/WO2023089328A1/en not_active Ceased
- 2022-11-18 MX MX2024006105A patent/MX2024006105A/es unknown
- 2022-11-18 CA CA3238805A patent/CA3238805A1/en active Pending
- 2022-11-18 IL IL312885A patent/IL312885A/en unknown
- 2022-11-18 AU AU2022392456A patent/AU2022392456A1/en active Pending
- 2022-11-18 US US18/710,477 patent/US20250000852A1/en active Pending
- 2022-11-18 JP JP2024527790A patent/JP2024540439A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022392456A1 (en) | 2024-05-23 |
| WO2023089328A1 (en) | 2023-05-25 |
| US20250000852A1 (en) | 2025-01-02 |
| JP2024540439A (ja) | 2024-10-31 |
| CA3238805A1 (en) | 2023-05-25 |
| KR20240108407A (ko) | 2024-07-09 |
| CN118215479A (zh) | 2024-06-18 |
| EP4433054A1 (en) | 2024-09-25 |
| IL312885A (en) | 2024-07-01 |
| GB202116743D0 (en) | 2022-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ775660A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| SA520412335B1 (ar) | مشتقات أوكسي فلورو ببريدين كمثبط كيناز | |
| MX2009008531A (es) | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. | |
| MY196186A (en) | Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor | |
| TNSN06228A1 (en) | Compounds and methods of use | |
| MX2025009723A (es) | Metodos de tratamiento contra adicciones | |
| PH12021550368A1 (en) | Dimethyl amino azetidine amides as jak inhibitors | |
| MX2023002323A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| MY202884A (en) | Compounds useful in hiv therapy | |
| PH12020550616A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| PH12021551873A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| MX2024004725A (es) | Metodos novedosos. | |
| WO2021089768A3 (en) | Treatment and prevention of a neurodegenerative disorder | |
| PH12022550448A1 (en) | Niclosamide delayed-release composition and antiviral use thereof | |
| MX2024006105A (es) | Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme. | |
| PH12019550138A1 (en) | Pharmaceutical combinations for treating cancer | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| ZA202204442B (en) | Salt forms of a complement component c5a receptor | |
| MX2023014530A (es) | Nitroxolina para su uso en el tratamiento de neurofibroma cutaneo. | |
| PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
| MY205944A (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| MX2021005944A (es) | Inhibidores de rip1. |